Gossamer Bio (NASDAQ: GOSS) — Company Overview, News & Financial Data
Gossamer Bio is a biopharmaceutical company dedicated to developing therapeutics in immunology, inflammation, and oncology.
Gossamer Bio
Gossamer Bio (NASDAQ:GOSS) is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics in the areas of immunology, inflammation, and oncology. With a focus on addressing unmet medical needs, Gossamer Bio is actively advancing a diverse portfolio of clinical and preclinical projects aimed at providing new treatment options for patients. The company's objectives are to leverage its scientific expertise and operational efficiency to bring novel therapies from the laboratory to the clinic as swiftly and safely as possible. Through strategic collaborations and a commitment to research excellence, Gossamer Bio strives to improve health outcomes and enhance the quality of life for people around the globe.
Snapshot
Operations
Products and/or services of Gossamer Bio
- Serabelisib, a PI3K delta inhibitor targeting hematologic malignancies.
- GB001, an oral DP2 antagonist for asthma and chronic rhinosinusitis.
- GB002, an inhaled PDGFR inhibitor for pulmonary arterial hypertension.
- GB004, an oral HIF-1 alpha stabilizer for ulcerative colitis.
- GB1275, an oral CD11b modulator for oncology indications.
- Research and development services focusing on innovative therapies for immunology, inflammation, and oncology.
Gossamer Bio executive team
- Faheem HasnainCo-Founder, CEO, President & Chairman
- Bryan GiraudoCOO & CFO
- Robert Paul Smith Jr.Chief Commercial Officer
- Christian WaageExecutive Vice President, Technical Operations & General Counsel
- Jeanine AnthonySenior Vice President of Marketing
- Deanna WeberExecutive Vice President of Human Resources
- Robert F. RoscignoSenior Vice President of Clinical Development of Pulmonary Vascular Disease
- Caryn L. PetersonChief Development Officer
- Kelly DawsonSenior Vice President & Program Team Lead
- Conor O'DonovanSenior Vice President of Regulatory Affairs
Key financials
Reported results for Gossamer Bio, in USD.
- Market cap
- 56.8M
- Revenue (TTM)
- 53.3M
- P/E ratio
- —
- EPS (diluted, TTM)
- -52.8
- Dividend yield
- —
- Profit margin
- -235.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 48.5M | -163.3M | -170.4M | |
| 114.7M | -59.9M | -56.5M | |
| 0 | -183.8M | -179.8M | |
| 0 | -218.6M | -229.4M |